Such variables could be time‐resolved organ dysfunction scores, inflammatory biomarkers (e.g., procalcitonin, IL‐6, CRP, etc.), baseline frailty, and oncologic details (e.g., cancer stage, treatment intent) to enable better stratification and identify subgroups of patients who may truly benefit from ICU interventions. The gene discussed is IL6; the disease is cancer.